Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration

Retina

Volumn 26, Issue 5, 2006, Pages 523-530

  Kim, Hyuncheol ^a   Csaky, Karl G ^a   Gravlin, Luisa ^b   Yuan, Peng ^b   Lutz, Robert J ^b   Bungay, Peter M ^b   Tansey, Ginger ^a   De Monasterio, Francisco ^a   Potti, Gopal K ^b   Grimes, George ^b   Robinson, Michael R ^a,c  

^a NATIONAL EYE INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c ALLERGAN INC   (United States)

Author keywords

Intravitreal injection; Ocular pharmacokinetics; Ocular toxicity; Retinal diseases; Triamcinolone acetonide

Indexed keywords

DRUG PRESERVATIVE; TRIAMCINOLONE ACETONIDE; EYE DROPS; GLUCOCORTICOID; PRESERVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; ELECTRORETINOGRAM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; NONHUMAN; RABBIT; TISSUE SECTION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG EFFECT; ELECTRORETINOGRAPHY; FEMALE; HALF LIFE TIME; INJECTION; MALE; PATHOLOGY; RETINA; VITREOUS BODY;

ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; ELECTRORETINOGRAPHY; FEMALE; GLUCOCORTICOIDS; HALF-LIFE; INJECTIONS; MALE; OPHTHALMIC SOLUTIONS; PRESERVATIVES, PHARMACEUTICAL; RABBITS; RETINA; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 33745801435     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200605000-00005     Document Type: Article

References (48)

1. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-927.
2. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61.
3. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001;108:765-772.
4. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol 2001;29:2-6.
5. Challa JK, Gillies MC, Penfold PL, et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 1998;26:277-281.
6. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-250.
7. Roth DB, Chieh J, Spirn MJ, et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003;121:1279-1282.
8. Sutter FK, Gillies MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 2003;87:972-974.
9. Nelson ML, Tennant MTS, Sivalingam A, et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003;23:686-691.
10. Moshfeghi AA, Scott IU, Flynn HW, Puliafito CA. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol 2004;138:489-492.
11. Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986;101:190-195.
12. Schlaegel TF Jr, Wilson FM. Accidental intraocular injection of depot corticosteroids. Trans Am Acad Ophthalmol Otolaryngol 1974;78:847.
13. Velez G, Yuan P, Sung C, et al. Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma. Arch Ophthalmol 2001;119:1518-1524.
14. Atkinson AJ Jr, Daniels CE, Dedrick RL, et al (eds). Principles of Clinical Pharmacology. 1st ed. London: Academic Press; 2001:460.
15. Andrew NC, Gregor ZJ. Intraocular injection of depomedrone. Br J Ophthalmol 1986;70:298-300.
16. Price NC, Cooling RJ, Andrew NC. The role of vitrectomy following accidental intraocular injection of deposteroid preparations. Trans Ophthalmol Soc U K 1986;105:469-472.
17. McCuen BW II, Bessler M, Tano Y, et al. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981;91:785-788.
18. Morrison VL, Kohl HJ, Cheng L, et al. Intravitreal toxicity of the Kenalog vehicle (benzyl alcohol) in rabbits. Invest Ophthalmol Vis Sci 2004;45:ARVO E-Abstract 1917.
19. Perlman I, Zemel E, Miller B, et al. Retinal toxicity of intravitreal Kenalog in albino rabbits. Invest Ophthalmol Vis Sci 2003;44:ARVO E-Abstract 4899.
20. Yu SY, Viola F, Damico FM, D'Amico DJ. Retinal toxicity of intravitreal triamcinolone acetonide: a morphologic study. Invest Ophthalmol Vis Sci 2004;45:ARVO E-Abstract 1930.
21. Gonzalo FE, Montagut LB, Vecina ST. Anaphylactic shock caused by triamcinolone acetonide. Ann Pharmacother 1994;28:1310.
22. Larsson LG. Anaphylactic shock after i.a. administration of triamcinolone acetonide in a 35-year-old female. Scand J Rheumatol 1989;18:441-442.
23. Brown WJ, Buist NR, Gipson HT, et al. Fatal benzyl alcohol poisoning in a neonatal intensive care unit. Lancet 1982;1:1250.
24. Gershanik J, Boecler B, Ensley H, et al. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med 1982;307:1384-1388.
25. Pesce AJ, McKean DL. Toxic susceptibilities in the newborn with special consideration of polysorbate toxicity. Ann Clin Lab Sci 1989;19:70-73.
26. Levy M, Dupuis LL. Parenteral nutrition hypersensitivity. J Parenter Enteral Nutr 1990;14:213-215.
27. Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet 1995;345:1312-1313.
28. Weiss RB. Hypersensitivity reactions. In: Perry MC, ed. The Chemotherapy Source Book. Philadelphia: Lippincott Williams & Wilkins; 2001:436-452.
29. Centers for Disease Control (CDS). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep 1984;33:198-199.
30. Siderov J, Prasad P, De Boer R, Desai J. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. Br J Cancer 2002;86:12-13.
31. Winkelman NW. Neurologic symptoms following accidental intraspinal detergent injection. Neurology 1952;284:284-291.
32. Moore DC, Hain RF, Ward A, Bridenbaugh LD. Importance of the perineural spaces in nerve blocking. JAMA 1954;156:1050-1053.
33. Hurst EW. Adhesive arachnoiditis and vascular blockage caused by detergents and other chemical irritants: an experimental study. J Pathol Bacteriol 1955;70:167-178.
34. Hetherington NJ, Dooley MJ. Potential for patient harm from intrathecal administration of preserved solutions. Med J Aust 2000;173:141-143.
35. Rodriguez-Coleman H, Yuan P, Kim H, et al. Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol 2004;122:1085-1086.
36. Steele AD, Andrews V. Methylcellulose for endothelial cell protection. Aust N Z J Ophthalmol 1988;16:251-254.
37. Fechner PU, Rimpler M. Comparison of hydroxypropyl methylcellulose 2% (Adatocel) and hyaluronic acid 1% (Healon). J Cataract Refract Surg 1989;15:685-688.
38. Chumbley LC, Morgan AM, Musallam I. Hydroxypropyl methylcellulose in extracapsular cataract surgery with intraocular lens implantation: intraocular pressure and inflammatory response. Eye 1990;4:121-126.
39. Fernandez-Vigo J, Refojo MF, Verstraeten T. Evaluation of a viscoelastic solution of hydroxypropyl methylcellulose as a potential vitreous substitute. Retina 1990;10:148-152.
40. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol 1985;103:1567-1569.
41. Diaz Gomez MI, Godoy HM, Marzi A, et al. Enhancement of the dimethylnitrosamine acute effects in rat liver by prior treatment with Triton WR-1339. J Natl Cancer Inst 1981;67:1089-1092.
42. Findlay RD, Taeusch HW, David-Cu R, Walther FJ. Lysis of red-blood-cells and alveolar epithelial toxicity by therapeutic pulmonary surfactants. Pediatr Res 1995;37:26-30.
43. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110:681-686.
44. Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982;93:415-417.
45. Robinson MR, Kim H, Gravlin L, et al. Preclinical evaluation of a triamcinolone acetonide preservative free (TAC-PF) formulation for intravitreal injection. Invest Ophthalmol Vis Sci 2004;45:ARVO E-Abstract 5058.
46. Pearson P, Baker CW, Eliott D, et al. Fluocinolone acetonide intravitreal implant in patients with diabetic macular edema: 12 month results. Invest Ophthalmol Vis Sci 2003;44: ARVO E-Abstract 4288.
47. Pearson PA, Jaffe GJ, Martin DF, et al. Evaluation of a delivery system providing long-term release of cyclosporine. Arch Ophthalmol 1996;114:311-317.
48. 14C- triamcinolone acetonide. J Pharm Sci 1976;65:429-430.